Tag - SRZN

Stifel launched coverage of Surrozen (NASDAQ:SRZN) with a “buy” rating and $19 target price. The stock closed at $7.24 on Sept. 3. Surrozen discovers and develops biologic drug candidates to selectively modulate the Wnt...